SynthesisBMC cancer2026
Association between ALK tyrosine kinase inhibitor and the risk of interstitial lung disease and pneumonitis in non-small cell lung cancer patients: a systematic review.
Synthesis in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Paradoxical Efficacy With Rare Adverse Events: Sequential ALK Inhibitor Therapy in Lung Adenocarcinoma.Clinical case reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundThis study aims to investigate the association between anaplastic lymphoma kinase tyrosine kinase inhibitors (ALK-TKIs) and the risks of interstitial lung disease (ILD) and pneumonitis in patients with non-small cell lung cancer (NSCLC).
methodsWe systematically searched PubMed, Embase, Cochrane Central Register of Controlled Trials for randomized controlled trials (RCTs) reporting ILD or pneumonitis events, from inception to April 2024. Pairwise and network meta-analyses were performed. Outcomes were overall/serious ILD and pneumonitis.
resultsA total of 14 RCTs involving 3859 participants were included. Results showed that ALK-TKIs significantly increased the risks of both overall ILD (RD = 0.01, 95%CI: 0.00 to 0.02, P = 0.048) and overall pneumonitis (RD = 0.01, 95%CI: 0.00 to 0.02, P = 0.039) compared to chemotherapy, while no significant difference existed in the risks of both serious ILD (RD = 0.01, 95%CI: -0.00 to 0.02, P = 0.130) and serious pneumonitis (RD = 0.01, 95%CI: -0.00 to 0.02, P = 0.109) between ALK-TKIs and chemotherapy. In the network meta-analysis (NMA), brigatinib was associated with significantly higher risks of both overall ILD and overall pneumonitis compared to crizotinib (OR = 8.87, 95%CI: 1.07 to 73.29; OR = 3.43, 95%CI: 1.00 to 11.71, respectively), alectinib (OR = 12.78, 95%CI: 1.56 to 104.98; OR = 6.09, 95%CI:1.57 to 23.68, respectively) and ceritinib (OR = 32.50, 95%CI: 1.05 to 1005.95; OR = 21.88, 95%CI: 1.78 to 268.53, respectively). Furthermore, the NMA revealed that brigatinib was associated with a significantly higher risk of serious pneumonitis compared to ceritinib (OR = 27.26, 95%CI: 1.33 to 558.33).
conclusionsALK-TKIs increase the risks of both ILD and pneumonitis in NSCLC patients, with brigatinib posing the highest probability among ALK-TKIs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.